ROS1 and non-small cell lung carcinoma: Brigatinib is an oral, potent, and selective ALK and ROS1 tyrosine kinase inhibitor, approved by the Food and Drug Administration (FDA) and European Medicine Agency (EMA) for patients with ALK positive NSCLC in progression on first-line crizotinib, and more recently for untreated patients.